Abstract:Highlights•In vitro 3D medulloblastoma models have indistinguishable transcriptomic profiles than the original tumor tissue.•One type of chemically defined media was identified to support four major types of pediatric brain tumor better than serum-containing culture conditions.•Different tumor types show varying spheroid-forming ability depending on stem cell composition in the original tumor cell population.•Different tumor types show different preference to 3D scaffold and/or extracellular matrix for the in vitro growth accompanied by microenvironment-induced gene expression changes.Brain tumors are the leading cause of cancer-related deaths in children. Tailored therapies need preclinical brain tumor models representing a wide range of molecular subtypes. Here, we adapted a previously established brain tissue-model to fresh patient tumor cells with the goal of establishing3D in vitro culture conditions for each tumor type.Wereported our findings from 11 pediatric tumor cases, consisting of three medulloblastoma (MB) patients, three ependymoma (EPN) patients, one glioblastoma (GBM) patient, and four juvenile pilocytic astrocytoma (Ast) patients. Chemically defined media consisting of a mixture of pro-neural and pro-endothelial cell culture medium was found to support better growth than serum-containing medium for all the tumor cases we tested. 3D scaffold alone was found to support cell heterogeneity and tumor type-dependent spheroid-forming ability; both properties were lost in 2D or gel-only control cultures. Limited in vitro models showed that the number of differentially expressed genes between in vitro vs. primary tissues, are 104 (0.6%) of medulloblastoma, 3,392 (20.2%) of ependymoma, and 576 (3.4%) of astrocytoma, out of total 16,795 protein-coding genes and lincRNAs. Two models derived from a same medulloblastoma patient clustered together with the patient-matched primary tumor tissue; both models were 3D scaffold-only in Neurobasal and EGM 1:1 (v/v) mixture and differed by a 1-mo gap in culture (i.e., 6wk versus 10wk). The genes underlying the in vitrovs. in vivo tissue differences may provide mechanistic insights into the tumor microenvironment. This study is the first step towards establishing a pipeline from patient cells to models to personalized drug testing for brain cancer.

Human stem cell models to unravel brain cancer

Stem cell modeling of nervous system tumors

In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies

Pediatric Tumors as Disorders of Development: The Case for In Vitro Modeling Based on Human Stem Cells

Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research

Building on a Solid Foundation: Adding Relevance and Reproducibility to Neurological Modeling Using Human Pluripotent Stem Cells

Human-mouse chimeric brain models constructed from iPSC-derived brain cells: Applications and challenges

Utilizing human cerebral organoids to model breast cancer brain metastasis in culture

Human pluripotent stem cell-derived brain organoids as in vitro models for studying neural disorders and cancer

3D patient-derived tumor models to recapitulate pediatric brain tumors In Vitro

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy

Animal models for brain tumors: historical perspectives and future directions

In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development

Glioblastoma preclinical models: Strengths and weaknesses

Cancer modeling meets human organoid technology

Advances and Applications of Brain Organoids

Emerging Human Pluripotent Stem Cell-Based Human–Animal Brain Chimeras for Advancing Disease Modeling and Cell Therapy for Neurological Disorders

Application of Human Brain Organoids—Opportunities and Challenges in Modeling Human Brain Development and Neurodevelopmental Diseases

Animal Models in Glioblastoma: Use in Biology and Developing Therapeutic Strategies

Human organoids: model systems for human biology and medicine

Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications